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J. Fung, and T.E. Starzl 
THE available clinical evidence suggests that careful 
control of plasma drug levels of FK 506 and thera-
peutic monitoring are important to balance the opposing 
risks of drug toxicity and graft rejection. I •2 An accurate 
and simple dosing algorithm that could be applied at 
bedside would facilitate standardization of patient manage-
ment. Therefore, a computerized dosing algorithm for FK 
506 and prednisone was developed. This "intelligent" 
dosing system (IDS) assumes no previous computer expe-
rience and operates on any IBM or IBM-compatible mi-
crocomputer system. 
The advantages of an accurate and simple automated 
drug dosing program include minimizing the learning curve 
for the physician prescribing the drug, particularly for 
drugs with large pharmacokinetic variability and a narrow 
therapeutic index. It should also improve patient care by 
reducing toxicity and decreasing the length of hospital stay 
experienced by patients. both of which should result in a 
cost-benefit advantage. 
The computerized dosing algorithm for FK 506 can best 
be described as an "expert system" utilizing stochastic 
open loop control theory.) Expert systems are computer 
programs that use a body of knowledge and specific rules 
to solve problems that are usually solved by human 
experts. In essence, an expert system uses what is called a 
"knowledge base" to solve problems. A knowledge base 
is a large body of information about a particular subject 
that is based on experience.) The expert system developed 
for FK 506 dosing is a prediction system that uses data 
about a patient's current state to predict the patient's 
future state based on a large body of empirical clinical 
experience with the drug in the patient of interest. Since 
individualization of FK 506 dosing is important, specific 
parameters of patient status have been incorporated into 
the decision matrix. In such a system, a "learned re-
sponse" is predicted based on previously obtained empiric 
experience. In this study, a dosing algorithm for FK 506 is 
described. In addition, the results of a prospective study 
designed to validate the accuracy and precision of the 
prediction capabilities of the program are reported. 
ALGORITHM 
The appropriate dosage of FK 506 and prednisone to be 
utilized for a given allograft recipient is a function of the 
patient's status, ie, level of graft function and whether or 
not any evidence of toxicity or rejection is present and the 
current plasma drug level. l •2 For example, if a given 
patient is demonstrating signs of drug toxicity, eg, either 
nephrotoxicity or hepatic dysfunction. and has no evi-
dence for rejection, then a reduction in either the FK 506 
dosage, the prednisone dosage, or both is indicated. On the 
other hand, if a patient has no evidence for drug toxicity 
and manifests signs of graft rejection, an increase in either 
the FK 506 dosage or the prednisone dosage or both may 
be in order, depending on the current FK 506 plasma level 
(see Fig I). The specific decision-making ability of the 
system is provided by a knowledge base containing facts 
and rules which have been determined empirically, which 
the system uses to define the best course of action. 
To determine FK 506 dosage required to achieve the 
desired target plasma level, an artificial intelligence dosing 
system (IDS) that would predict drug dosages and levels 
was developed. This IDS was programmed with hundreds 
of dosing histories, ie, previous dose. previous level, 
current dose. and current level. The system was then used 
as a model to develop an equation that relates the current 
FK 506 dose and level with the desired dose and level. To 
use the dosing algorithm, the physician enters the patient's 
current FK 506 dose (total milligrams per day), the pa-
tient's current plasma level (nanograms per milliliter), and 
the target plasma level (nanograms per milliliter). The IDS 
calculates the FK 506 dose required to achieve the target 
level. The IDS can also be used to predict the next FK 506 
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Fig 1. Dosing example. 
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Fig 2. Observed versus predicted plasma levels. 
level given the patients current FK 506 dose, current FK 
506 level, and the new FK 506 dose. 
RESULTS 
To validate the IDS. a prospective study was conducted at 
the University of Pittsburgh Health Center. The patient 
population studied consisted of 32 adult liver (n = 17) and 
kidney (n = 15) transplant patients. Predictions of patient 
plasma blood levels were made throughout their clinical 
course which included the use of both IV (postoperative) 
and oral (maintenance) dosing with FK 506. 
The mean prediction error (mpe), calculated as the mean 
difference between the observed and the predicted target 
values, was used to describe the model's accuracy. If the 
model was perfect. the mpe would be zero. The accuracy 
of the model was calculated to be 0.016 ng/mL. The root 
mean squared prediction error (rmspe), calculated as the 
standard deviation of the prediction errors, was used to 
describe the precision of the model. The root mean 
squared prediction error was calculated to be 0.189 ng/mL. 
The 95% confidence interval for the mean prediction error 
was calculated to be between 0.084 and 0.052. which 
brackets our calculated accuracy (including zero). This 
means that the model is 95% accurate in describing the 
relationship between FK 506 dosage and FK 506 plasma 
level, and that there are no biases in the dosing predic-
tions. The accuracy of this IDS is illustrated in Fig 2, 
which shows the close correlation between the observed 
and predicted FK 506 plasma levels. 
The "intelligent" portion of the program, the part that 
decides what action should be taken, was modeled after 
the clinical judgment of knowledgeable physicians practic-
ing at the University of Pittsburgh Health Center who have 
had considerable clinical experience using FK 506 in 
transplant patients. 
DISCUSSION 
The use of artificial intelligence (AI) is a novel approach to 
understand and describe what has been observed in a 
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Fig 3. IDS algOrithm. 
complex biological situation based on specific knowledge 
and inference techniques. 3 By using standard AI methods 
and tools. it has been possible to define and model phar-
macokinetic (PK) events and important PK-pharmacody-
namic (PO) relationships, which are essential for clinical 
dosing decisions with FK 506 in transplant patients. As a 
result, this IDS can be used clinically to provide accurate 
predictions of clinical events associated with transplanta-
tion. For example, it is possible to predict the effect a 
specific change in FK 506 dose has on either toxicity or 
rejection. Because the model developed is a multiparame-
ter system, more complex models can be built that de-
scribe such PK-PD relationships in a multivariate fashion. 
For example, a model could be constructed to identify the 
patient factors or covariates commonly involved in cases 
of rejection and/or toxicity. Furthermore, the current 
dose, new dose, and percent change in FK 506 level can be 
plotted to generate a three-dimensional graph or kinetic 
profile of the drug. This method allows for the direct 
comparison of the kinetic profiles of various drugs such 
that clinically important properties, ie, "linearity" and 
"dose proportionality" can be visualized (manuscript in 
preparation). 
Importantly, the IDS developed is very user friendly. It 
has been routinely used by transplant physicians without 
previous computer training or experience. To run the 
program the physician is asked to make choices from 
menus to answer questions about a patient's condition. 
The only keyboard input required is to enter the values 
(current FK 506 doses and levels, etc) which are used to do 
the dose calculations. The critical components of the IDS 
algorithm are shown in Fig 3. This IDS makes predictions 
based on the patient's previous dosing experience, and has 
been shown to accurately predict appropriate alterations in 
FK 506 and prednisone dosages. The flexibility of the 
model is such that it could be modified to account for 
additional parameters, such as a third immunosuppressive 
agent. 
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The experience with this IDS suggest that a user-
friendly. PC-based dosing system can efficiently individu-
alize and optimize FK 506 therapy. and should simplify the 
physician learning curve relative to the use of FK 506. 
while maximizing patient care and providing an effective 
means for conducting concentration-controlled clinical tri-
als with FK 506. 
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